Sort
48,018 grants matching “immunotherapy”
Optimization of an active mutant KRAS peptide vaccine in colorectal cancer
$589,838Nilofer S. Azad · Johns Hopkins University · R01 · FY2025 · CA
Embryonic natural killer cell development and function
$589,798Christopher Michael Sturgeon · Washington University · R01 · FY2020 · HL
Neoadjuvant immunoradiotherapy for HPV mediated oropharynx cancer
$589,762Joseph A Califano · University Of California, San Diego · R01 · FY2024 · CA
Novel immunological biomarkers ovarian cancer prognosis
$589,735Brahm H. Segal · Roswell Park Cancer Institute Corp · R01 · FY2015 · CA
Neural and Immune Correlates of Painful Chemotherapy-Induced Neuropathy, Feasibility and Preliminary Efficacy of a Motor Cortex Non-Invasive Brain Stimulation Intervention
$589,727Timothy J Meeker · Morgan State University · U54 · FY2025 · MD
Two-way Magnetic Resonance Tuning Nanoprobe Enhanced Subtraction Imaging for Precision Diagnosis of Brain Metastasis
$589,688Yuanpei Li · University Of California At Davis · R01 · FY2024 · EB
Immunometabolic Programs Controlled by ER Stress in Cancer
$589,582Juan R Cubillos-Ruiz · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA
Planning and Evaluation
$589,515Robert L Ferris · Univ Of North Carolina Chapel Hill · P30 · FY2025 · CA
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse
$589,497Shulin Li · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · NS
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse
$589,497Shulin Li · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · NS
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse
$589,497Shulin Li · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · NS
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
$589,450Robert J Gray · Dana-Farber Cancer Inst · U01 · FY2021 · CA
The interplay of social and molecular determinants in lung cancer disparity
$589,299Shailesh Singh · Morehouse School Of Medicine · R01 · FY2025 · CA
The interplay of social and molecular determinants in lung cancer disparity
$589,297Shailesh Singh · Morehouse School Of Medicine · R01 · FY2022 · CA
Targeting tumor metabolism and immune environment via beta-catenin: Towards precision medicine in HCC
$589,164Satdarshan Singh Monga · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA
Strategies for Distinguishing Success in Immunotherapy Treatments (PQ20)
$589,162James R. Heath · California Institute Of Technology · R01 · FY2013 · CA
Finding the optimal balance of immunotherapy efficacy and toxicity.
$589,033David Eric Gerber · Ut Southwestern Medical Center · U01 · FY2020 · AI
Vascular macrophages and T cells in atherosclerosis
$588,993Klaus F. Ley · La Jolla Institute For Immunology · R35 · FY2022 · HL
Credentialing Mouse Models for Immune System Therapy Research
$588,966Charles M Perou · Univ Of North Carolina Chapel Hill · R01 · FY2015 · CA
New tools for tracking single cells in vivo
$588,962Guillem Pratx · Stanford University · R01 · FY2023 · EB
Glycosylation and Immune Evasion in Urologic Tumors
$588,870Sharon Pitteri · Stanford University · U01 · FY2022 · CA
Elucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer Immunotherapy
$588,833Jun Wang · New York University School Of Medicine · R37 · FY2022 · CA
Intravenous VSV virotherapy in lymphoma
$588,765Kah-Whye Peng · Mayo Clinic Rochester · R01 · FY2024 · CA
Immunology of aging and immunotherapy of aging-associated diseases
$588,623Arya Biragyn · National Institute On Aging · ZIA · FY2017 · AG
Towards True Precision Oncology: Validation of a Comprehensively Humanized, Autologous Mouse Model
$588,621Ryan C Fields · Washington University · R01 · FY2018 · CA